634 related articles for article (PubMed ID: 2504890)
1. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
2. Dana-Farber Cancer Institute studies in advanced sarcoma.
Antman KH; Elias A
Semin Oncol; 1990 Feb; 17(1 Suppl 2):7-15. PubMed ID: 2106162
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
Elias AD; Antman KH
Cancer Treat Rep; 1986 Jul; 70(7):827-33. PubMed ID: 3087617
[TBL] [Abstract][Full Text] [Related]
4. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
[TBL] [Abstract][Full Text] [Related]
5. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.
Elias A; Ryan L; Aisner J; Antman KH
Semin Oncol; 1990 Apr; 17(2 Suppl 4):41-9. PubMed ID: 2110385
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Huang YH; Wen XP; Hu L
Ai Zheng; 2002 Aug; 21(8):907-9. PubMed ID: 12478905
[TBL] [Abstract][Full Text] [Related]
9. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
Leyvraz S; Bacchi M; Cerny T; Lissoni A; Sessa C; Bressoud A; Hermann R
Ann Oncol; 1998 Aug; 9(8):877-84. PubMed ID: 9789611
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of advanced sarcomas of bone and soft tissue.
Antman KH
Semin Oncol; 1992 Dec; 19(6 Suppl 12):13-20. PubMed ID: 1485169
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
Wiklund TA; Blomqvist CP; Virolainen M; Elomaa I
Cancer Chemother Pharmacol; 1992; 30(2):100-4. PubMed ID: 1600589
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.
González-Manzano R; Vieitez JM; Tangco E; Fernandez de Alava E; Herranz P; Garcia-Foncillas J
Am J Clin Oncol; 1993 Aug; 16(4):332-7. PubMed ID: 8328412
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
Cantwell BM; Carmichael J; Ghani S; Harris AL
Cancer Chemother Pharmacol; 1988; 21(1):49-52. PubMed ID: 3124971
[TBL] [Abstract][Full Text] [Related]
15. [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
Li EX; Zhang YT; Shang JT; Xu Z; Geng Y; Li SM; Shi F; Wu YY
Ai Zheng; 2006 Aug; 25(8):1048-51. PubMed ID: 16965692
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
Weh HJ; Zügel M; Wingberg D; Schwarz R; Zornig C; Dietel M; Hossfeld DK
Onkologie; 1990 Dec; 13(6):448-52. PubMed ID: 2128712
[TBL] [Abstract][Full Text] [Related]
17. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas.
Toma S; Palumbo R; Canavese G; Albanese E; Cantoni E; Barisone A; Reggiardo G; Rosso R; Santi L
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S222-7. PubMed ID: 8453703
[TBL] [Abstract][Full Text] [Related]
19. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Le Cesne A; Antoine E; Spielmann M; Le Chevalier T; Brain E; Toussaint C; Janin N; Kayitalire L; Fontaine F; Genin J
J Clin Oncol; 1995 Jul; 13(7):1600-8. PubMed ID: 7541449
[TBL] [Abstract][Full Text] [Related]
20. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
